全文获取类型
收费全文 | 1399篇 |
免费 | 77篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 58篇 |
妇产科学 | 39篇 |
基础医学 | 198篇 |
口腔科学 | 29篇 |
临床医学 | 122篇 |
内科学 | 287篇 |
皮肤病学 | 40篇 |
神经病学 | 107篇 |
特种医学 | 31篇 |
外科学 | 128篇 |
综合类 | 22篇 |
一般理论 | 9篇 |
预防医学 | 94篇 |
眼科学 | 90篇 |
药学 | 120篇 |
中国医学 | 8篇 |
肿瘤学 | 89篇 |
出版年
2024年 | 1篇 |
2023年 | 13篇 |
2022年 | 42篇 |
2021年 | 62篇 |
2020年 | 41篇 |
2019年 | 69篇 |
2018年 | 55篇 |
2017年 | 44篇 |
2016年 | 62篇 |
2015年 | 47篇 |
2014年 | 83篇 |
2013年 | 108篇 |
2012年 | 135篇 |
2011年 | 120篇 |
2010年 | 55篇 |
2009年 | 63篇 |
2008年 | 87篇 |
2007年 | 85篇 |
2006年 | 54篇 |
2005年 | 76篇 |
2004年 | 45篇 |
2003年 | 51篇 |
2002年 | 31篇 |
2001年 | 7篇 |
2000年 | 3篇 |
1999年 | 3篇 |
1998年 | 7篇 |
1997年 | 4篇 |
1996年 | 2篇 |
1995年 | 5篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1987年 | 3篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1982年 | 3篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有1480条查询结果,搜索用时 15 毫秒
21.
Colorectal endoscopic submucosal dissection: Systematic review of mid‐term clinical outcomes 下载免费PDF全文
Nisha Patel Kinesh Patel Hutan Ashrafian Thanos Athanasiou Ara Darzi Julian Teare 《Digestive endoscopy》2016,28(4):405-416
With a drive towards minimally invasive surgery, endoscopic submucosal dissection (ESD) is now gaining popularity. In a number of East Asian countries, ESD is now the treatment of choice for early non‐metastatic gastric cancer, but the outcomes of ESD for colorectal lesions are unclear. The present review summarizes the mid‐term outcomes of colorectal ESD including complication and recurrence rates. A systematic literature search was done in May 2014, identifying 20 publications reporting the outcomes of colorectal ESD which were included in this review. En‐bloc resection rates, complete (R0) resection rates, endoscopic clearance rates, complication and recurrences rates were analyzed. Statistical pooling was done to calculate weighted means using random effects modeling. Twenty studies reporting the outcomes of 3060 colorectal ESD procedures were reported. Overall weighted en‐bloc resection rate was 89% (95% CI: 83–94%), R0 resection rate 76% (95% CI: 69–83%), endoscopic clearance rate 94% (95% CI: 90–97%) and recurrence rate 1% (95% CI: 0.5–2%). Studies that followed up patients for over 1 year were found to have an en‐bloc resection rate of 91% (95% CI: 86–96%), R0 resection rate of 81% (95% CI: 75–88%), endoscopic clearance rate 93% (95% CI: 90–97%) and recurrence rate of 0.8% (95% CI: 0.4–1%). Colorectal ESD can be carried out effectively and safely with a 1% recurrence rate. Further studies with longer follow‐up periods are required to determine whether colorectal ESD is a viable alternative to conventional surgical therapy. 相似文献
22.
23.
Vitamin B12 deficiency has been associated with significant neurological pathology, especially peripheral neuropathy. This review aims to examine the existing evidence on the effectiveness of vitamin B12 supplementation for the treatment of diabetic peripheral neuropathy. A search of PubMed and the Cochrane Central Register of Controlled Trials for all relevant randomised controlled trials was conducted in December 2014. Any type of therapy using vitamin B12 or its coenzyme forms was assessed for efficacy and safety in diabetics with peripheral neuropathy. Changes in vibration perception thresholds, neuropathic symptoms and nerve conduction velocities, as well as the adverse effects of vitamin B12 therapy, were assessed. Four studies comprising 363 patients met the inclusion criteria. This review found no evidence that the use of oral vitamin B12 supplements is associated with improvement in the clinical symptoms of diabetic neuropathy. Furthermore, the majority of studies reported no improvement in the electrophysiological markers of nerve conduction. 相似文献
24.
25.
Nisha Marwah Shilpi Modi Veena Gupta Sumiti Gupta Gajender Singh Rajeev Sen 《Indian journal of hematology & blood transfusion》2012,28(1):47-49
We report a case of a newborn male who had mongoloid slant and was hypotonic at birth. Routine investigations revealed leucocytosis
(WBC > 70,000/cmm) with 50% blasts in peripheral blood film. Marrow examination confirmed the excess of blasts. Karyotyping
revealed 47, XY + 21 chromosomes. Due to absence of clinical symptoms, the baby was kept on follow-up without treatment. Within
7 weeks, PBF and bone marrow findings returned to normal, and the child was diagnosed as having Transient leukaemia with Down
syndrome. 相似文献
26.
27.
Shuaizhang Li Jinghua Zhao Ruili Huang Jameson Travers Carleen Klumpp-Thomas Wenbo Yu Alexander D. MacKerell Jr. Srilatha Sakamuru Masato Ooka Fengtian Xue Nisha S. Sipes Jui-Hua Hsieh Kristen Ryan Anton Simeonov Michael F. Santillo Menghang Xia 《Environmental health perspectives》2021,129(4)
Background: Inhibition of acetylcholinesterase (AChE), a biomarker of organophosphorous and carbamate exposure in environmental and occupational human health, has been commonly used to identify potential safety liabilities. So far, many environmental chemicals, including drug candidates, food additives, and industrial chemicals, have not been thoroughly evaluated for their inhibitory effects on AChE activity. AChE inhibitors can have therapeutic applications (e.g., tacrine and donepezil) or neurotoxic consequences (e.g., insecticides and nerve agents).Objectives: The objective of the current study was to identify environmental chemicals that inhibit AChE activity using in vitro and in silico models.Methods: To identify AChE inhibitors rapidly and efficiently, we have screened the Toxicology in the 21st Century (Tox21) 10K compound library in a quantitative high-throughput screening (qHTS) platform by using the homogenous cell-based AChE inhibition assay and enzyme-based AChE inhibition assays (with or without microsomes). AChE inhibitors identified from the primary screening were further tested in monolayer or spheroid formed by SH-SY5Y and neural stem cell models. The inhibition and binding modes of these identified compounds were studied with time-dependent enzyme-based AChE inhibition assay and molecular docking, respectively.Results: A group of known AChE inhibitors, such as donepezil, ambenonium dichloride, and tacrine hydrochloride, as well as many previously unreported AChE inhibitors, such as chelerythrine chloride and cilostazol, were identified in this study. Many of these compounds, such as pyrazophos, phosalone, and triazophos, needed metabolic activation. This study identified both reversible (e.g., donepezil and tacrine) and irreversible inhibitors (e.g., chlorpyrifos and bromophos-ethyl). Molecular docking analyses were performed to explain the relative inhibitory potency of selected compounds.Conclusions: Our tiered qHTS approach allowed us to generate a robust and reliable data set to evaluate large sets of environmental compounds for their AChE inhibitory activity. https://doi.org/10.1289/EHP6993 相似文献
28.
Nisha C. Hazra Caroline Rudisill Martin C. Gulliford 《The European journal of health economics》2018,19(6):831-842
Ageing is assumed to be accompanied by greater health care expenditures but the association is also viewed as a ‘red herring’. This study aimed to evaluate whether age is associated with health care costs in the senior elderly, using electronic health records for 98,220 participants aged 80 years and over registered with the UK Clinical Practice Research Datalink and linked Hospital Episode Statistics (2010–2014). Annual costs of health care utilization were estimated from a two-part model; multiple fractional polynomial models were employed to evaluate the non-linear association of age with predicted health care costs while also controlling for comorbidities, impairments, and death proximity. Annual health care costs increased from 80 years (£2972 in men, £2603 in women) to 97 (men; £4721) or 98 years (women; £3963), before declining. Costs were significantly elevated in the last year of life but this effect declined with age, from £10,027 in younger octogenarians to £7021 in centenarians. This decline was steeper in participants with comorbidities or impairments; £14,500 for 80–84-year-olds and £6752 for centenarians with 7+ impairments. At other times, comorbidity and impairments, not age, were main drivers of costs. We conclude that comorbidities, impairments, and proximity to death are key mediators of age-related increases in health care costs. While the costs of comorbidity among survivors are not generally associated with age, additional costs in the last year of life decline with age. 相似文献
29.
30.